Canada wants industry feedback on plans to extend GMP to APIs

Canada wants industry feedback on GMP for API plan

Related tags Pharmacology Pharmaceutical drug Active ingredient

Regulator Health Canada has started a consultation on plans to extend GMP requirements to active pharmaceutical ingredients (API).

The organisation first mooted the idea of extending good manufacturing practice (GMP) laws to include APIs in September in a document published in the Canada Gazette​, however it only began seeking industry feedback this week.

At present in Canada GMP only applies to dosage forms and ingredients that are deemed to be ‘high-risk.’ Standard APIs in contrast are not covered by GMP and instead their quality is assessed through testing before they are used.

Health Canada argues that because this testing “cannot eliminate all risks” or be applied retroactively, the rules need to be revised.

The plan is to “This proposal would extend the drug GMP requirements set out in the Food and Drug Regulations such that they apply to all APIs.

It would also “extend the drug establishment licensing (EL) requirements set out in the Food and Drug Regulations such that they apply to all AI fabricators, packagers/labellers, testers and importers​.”

Health Canada suggested that extending GMP to APIs would “create a new record-keeping requirement to foster the traceability of AI from the original fabricator to the dosage-form drug manufacturer.​”

The regulator suggested that the move would yield a financial benefit for the country.

This proposal would provide a net benefit to Canadians, with a net present value (NPV) of about $35.6 million over 10 years. The quantified benefits relate primarily to costs savings to industry due to the removal of poor quality drug products at the AI stage instead of recalls at the dosage-form stage​.”

It also believes that: “Industry is expected to incur minimal incremental compliance costs as the majority already complies with the international guideline for export purposes​.”

The consultation period will run until January 5.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars